Actively Recruiting
Long-Term Safety of Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma
Led by Eli Lilly and Company · Updated on 2026-03-02
279
Participants Needed
36
Research Sites
135 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This research aims to assess the long-term safety and effectiveness of pirtobrutinib in people who have previously been treated for Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma. It is a Phase 4 study involving participants who completed an earlier study called LOXO-BTK-18001. The study invites these participants to continue their assigned treatment or follow-up in this extension study. Participants will continue receiving pirtobrutinib, which is taken orally, as they did in the original study. This study serves as an individual-study appendix under the master protocol J2N-MC-JZNY. There are no new treatment groups; participants maintain the therapy they were assigned before. During the study, participants will be monitored for serious treatment-related side effects, including tracking any grade 3 or higher adverse events occurring from the first dose through 30 days after the last dose or until starting a new cancer therapy. Researchers will also observe overall survival up to 93 months from enrollment in the original study. Participants will have regular follow-up visits to assess their health and treatment safety over the long term.
CONDITIONS
Brief Title
A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Currently enrolled and active in the original LOXO-BTK-18001 study
- Active status includes receiving study intervention, short-term follow-up, or long-term follow-up
- Aged 18 years or older
- All genders are eligible
You will not qualify if you...
- Participation in the Phase 1b cohort of the LOXO-BTK-18001 study
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - From the first dose until discontinuation of pirtobrutinib.
Participants receive pirtobrutinib orally as part of their treatment.
Trial Site Locations
Total: 36 locations
1
Sylvester Comprehensive Cancer Center
Miami, Florida, United States, 33136-1002
Actively Recruiting
2
Florida Cancer Specialists
Sarasota, Florida, United States, 34232-6422
Actively Recruiting
3
The Emory Clinic
Atlanta, Georgia, United States, 30322-1013
Actively Recruiting
4
Northwestern University
Chicago, Illinois, United States, 60611-3013
Actively Recruiting
5
Dana-Farber Cancer Institute
Boston, Massachusetts, United States, 02115
Actively Recruiting
6
Mayo Clinic- Minnesota
Rochester, Minnesota, United States, 55905
Actively Recruiting
7
University Of Nebraska Medical Center
Omaha, Nebraska, United States, 69198
Actively Recruiting
8
Cayuga Cancer Center
Ithaca, New York, United States, 14850
Active, Not Recruiting
9
Northwell Health
Lake Success, New York, United States, 11042-1118
Actively Recruiting
10
Memorial Sloan-Kettering Cancer Center (MSKCC) - New York
New York, New York, United States, 10065-6007
Actively Recruiting
11
Memorial Sloan-Kettering Cancer Center (MSKCC) - New York
New York, New York, United States, 10065-6007
Active, Not Recruiting
12
Duke University Medical Center
Durham, North Carolina, United States, 27710-4000
Actively Recruiting
13
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, United States, 43210-1063
Actively Recruiting
14
University of Pennsylvania Hospital
Philadelphia, Pennsylvania, United States, 19104
Actively Recruiting
15
Tennessee Oncology
Nashville, Tennessee, United States, 37203-2659
Actively Recruiting
16
University of Texas MD Anderson Cancer Center
Houston, Texas, United States, 77030-4000
Actively Recruiting
17
Swedish Cancer Institute
Seattle, Washington, United States, 98104-3588
Actively Recruiting
18
Medical College of Wisconsin
Milwaukee, Wisconsin, United States, 53226-3548
Actively Recruiting
19
Flinders Medical Centre
Adelaide, Australia, 5042
Actively Recruiting
20
Peter MacCallum Cancer Centre
Melbourne, Australia, 3000
Completed
21
Linear Clinical Research
Victoria, Australia, 3000
Active, Not Recruiting
22
CHU de Nantes - Hotel Dieu
Nantes, France, 44093
Actively Recruiting
23
IRCCS-AOU di Bologna-Policlinico S.Orsola-Malpighi
Bologna, Italy, 40138
Completed
24
Ospedale San Raffaele
Milan, Italy, 20132
Actively Recruiting
25
Nagoya Medical Center
Aichi-Ken, Japan, 4600001
Active, Not Recruiting
26
National Cancer Center Hospital
Cho-ku, Japan, 104-0045
Completed
27
National Hospital Organization Kyushu Cancer Center
Fukuoka, Japan, 811-1395
Active, Not Recruiting
28
Tokai University Hospital- Isehara Campus
Isehara, Japan, 259-1193
Active, Not Recruiting
29
Tohoku University Hospital
Miyagi-Ken, Japan, 9808574
Active, Not Recruiting
30
Hokkaido University Hospital
Sapporo, Japan, 060-8648
Active, Not Recruiting
31
Pratia MCM Krakow
Krakow, Poland, 30727
Actively Recruiting
32
Instytut Hermatologii I Transfuzjologii
Warsaw, Poland, 02-776
Actively Recruiting
33
Seoul National University Hospital
Seoul, South Korea, 03080
Actively Recruiting
34
St James's University Hospital
Leeds, United Kingdom, LS9 7TF
Actively Recruiting
35
Churchill Hospital
Oxford, United Kingdom, OX3 7LE
Actively Recruiting
36
Derriford Hospital
Plymouth, United Kingdom, PL6 8DH
Actively Recruiting
Research Team
T
Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
P
Physicians interested in becoming principal investigators please contact
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here